Trial · NCT04533737
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Having Psoriasis Area and Severity Index (PASI) 100 Response at Week 16 | Week 16 | FAS | percentage of subjects | LEAST_SQUARES_MEAN |
| SECONDARY | Time to PASI 100 Response (Summarized as the Cumulative Incidence for Achieving PASI 100 at Each Timepoint, Stratified by Weight) | up to 28 weeks | FAS | percentage of subjects | NUMBER |
| SECONDARY | Time to PASI 90 Response (Summarized as the Cumulative Incidence for Achieving PASI 90 at Each Timepoint, Stratified by Weight) | up to 28 weeks | FAS | percentage of subjects | NUMBER |
| SECONDARY | Having PASI 100 Response, Assessed Separately at Weeks 4, 8, and 28. | Weeks 4, 8, and 28 | FAS | percentage of participants | LEAST_SQUARES_MEAN |
| SECONDARY | Having PASI 90 Response, Assessed Separately at Weeks 4, 8, 16, and 28. | Weeks 4, 8, 16, and 28 | FAS | percentage of participants | LEAST_SQUARES_MEAN |
| SECONDARY | Having Investigator's Global Assessment (IGA) of 0, Assessed Separately at Weeks 16 and 28. | Weeks 16 and 28 | FAS | percentage of participants | LEAST_SQUARES_MEAN |
| SECONDARY | Having IGA of 0 or 1, Assessed Separately at Weeks 16 and 28. | Weeks 16 and 28 | FAS | percentage of participants | LEAST_SQUARES_MEAN |
| SECONDARY | Having Dermatology Life Quality Index (DLQI) Total Score of 0 or 1, Assessed Separately at Weeks 4, 8, 12, 16, 20, 24, and 28. | Weeks 4, 8, 12, 16, 20, 24, and 28 | FAS | percentage of participants | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Score From Baseline, Assessed Separately at Weeks 4, 8, 16, and 28. | Weeks 4, 8, 16, and 28 | FAS | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in 36-Item Short Form Health Survey Version 2 (SF-36v2) Mental Component Score From Baseline, Assessed Separately at Weeks 4, 8, 16, and 28. | Weeks 4, 8, 16, and 28 | FAS | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Occurrence of Treatment-emergent Adverse Events (AEs) From Baseline to Week 28. | From baseline to Week 28 | Safety analysis set | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04533737/outcomes